DB ups Roche to 'buy' on positive oncology survey

By Reuters News

** Deutsche Bank DBKGn.DE upgrades Swiss healthcare company Roche ROPC.S to "buy" from "hold" driven by positive physician feedback from a proprietary oncology survey

** DB notes that physician sentiment on breast cancer treatment giredestrant has leaned positive for some time with implications resonating in the near term

** Analysts at the bank admit being "late to a consensus trade" but argue they see little obvious reason for a better entry point into the stock anytime soon

** They add that immediate pipeline risks have diminished while modest expectations for fenebrutinib mean multiple sclerosis data offer limited concern

** Out of 24 analysts that cover the stock, 12 rate the it "strong buy" or "buy", ​10 rate it "hold" and 2​ rate it "strong sell" or "sell" - LSEG data

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.